Global (United States, European Union and China) Gastrointestinal Cancer Drugs
Global (United States, European Union and China) Gastrointestinal Cancer Drugs

Gastrointestinal Cancer Drugs Comprehensive Study by Application (Hospitals, Specialized Cancer Treatment Centers, Clinics, Ambulatory Surgical Centers), Drug Type (Ramucirumab, Docetaxel, Doxorubicin Hydrochloride, Fluorouracil, Others), Therapy (Immunotherapy, Chemotherapy, Targeted Therapy, Sunitinib, Trastuzumab, Imatinib, Hormone Therapy, Adjuvant Chemotherapy, Radiation Therapy, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online, Others) Players and Region - Global Market Outlook to 2025

Gastrointestinal Cancer Drugs Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Jul 2020 Edition 242 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Scope of the Study

Gastrointestinal cancer refers to the group of cancers associated with the gastrointestinal tract (GI tract) and accessory organs of digestion, including the esophagus, stomach, biliary system, pancreas, small intestine, large intestine, rectum and anus. The treatment of this type of cancer depends on each patient's type and stage of cancer as well as the patient's age, overall health and preferences.

The market study is being classified, by Application (Hospitals, Specialized Cancer Treatment Centers, Clinics and Ambulatory Surgical Centers) and major geographies with country level break-up.

Bristol-Myers Squibb Company (United States), Roche Holding AG (Switzerland), Eli Lilly and Company (United States), Johnson & Johnson (United States), GlaxoSmithKline plc. (United Kingdom), Celgene Corporation (United States), Pfizer Inc. (United States), Sanofi S.A. (France), Novartis AG (Switzerland) and AstraZeneca (United Kingdom) are some of the key players profiled in the study.

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Gastrointestinal Cancer Drugs market throughout the predicted period.

Segment Analysis
AdvanceMarketAnalytics has segmented the market of Global Gastrointestinal Cancer Drugs market by Type, Application and Region.

On the basis of geography, the market of Gastrointestinal Cancer Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increased Prevalence of Gastrointestinal Cancers
  • Huge Investments by the Major Players

Market Trend
  • Advancements in the Medical Science
  • Increased Research and Development Activities

Restraints
  • Side Effects of the Cancer Drugs

Opportunities
  • Growth in the Health Care Industry Worldwide
  • Growing Geriatric Population Worldwide
  • Robust Increase in the Distribution Channels

Challenges
  • Stringent Government Rules and Regulations





Key Target Audience
Gastrointestinal Cancer Drugs Manufacturers, Raw Material Suppliers, Distributors, Emerging Companies and End-users

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Application
  • Hospitals
  • Specialized Cancer Treatment Centers
  • Clinics
  • Ambulatory Surgical Centers
By Drug Type
  • Ramucirumab
  • Docetaxel
  • Doxorubicin Hydrochloride
  • Fluorouracil
  • Others

By Therapy
  • Immunotherapy
  • Chemotherapy
  • Targeted Therapy
  • Sunitinib
  • Trastuzumab
  • Imatinib
  • Hormone Therapy
  • Adjuvant Chemotherapy
  • Radiation Therapy
  • Others

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Gastrointestinal Cancers
      • 3.2.2. Huge Investments by the Major Players
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Advancements in the Medical Science
      • 3.4.2. Increased Research and Development Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Gastrointestinal Cancer Drugs, by Application, Drug Type, Therapy, Distribution Channel and Region (value, volume and price ) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Gastrointestinal Cancer Drugs (Value)
      • 5.2.1. Global Gastrointestinal Cancer Drugs by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Specialized Cancer Treatment Centers
        • 5.2.1.3. Clinics
        • 5.2.1.4. Ambulatory Surgical Centers
      • 5.2.2. Global Gastrointestinal Cancer Drugs by: Drug Type (Value)
        • 5.2.2.1. Ramucirumab
        • 5.2.2.2. Docetaxel
        • 5.2.2.3. Doxorubicin Hydrochloride
        • 5.2.2.4. Fluorouracil
        • 5.2.2.5. Others
      • 5.2.3. Global Gastrointestinal Cancer Drugs by: Therapy (Value)
        • 5.2.3.1. Immunotherapy
        • 5.2.3.2. Chemotherapy
        • 5.2.3.3. Targeted Therapy
        • 5.2.3.4. Sunitinib
        • 5.2.3.5. Trastuzumab
        • 5.2.3.6. Imatinib
        • 5.2.3.7. Hormone Therapy
        • 5.2.3.8. Adjuvant Chemotherapy
        • 5.2.3.9. Radiation Therapy
        • 5.2.3.10. Others
      • 5.2.4. Global Gastrointestinal Cancer Drugs by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharmacies
        • 5.2.4.2. Retail Pharmacies
        • 5.2.4.3. Online
        • 5.2.4.4. Others
      • 5.2.5. Global Gastrointestinal Cancer Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Gastrointestinal Cancer Drugs (Volume)
      • 5.3.1. Global Gastrointestinal Cancer Drugs by: Application (Volume)
        • 5.3.1.1. Hospitals
        • 5.3.1.2. Specialized Cancer Treatment Centers
        • 5.3.1.3. Clinics
        • 5.3.1.4. Ambulatory Surgical Centers
      • 5.3.2. Global Gastrointestinal Cancer Drugs by: Drug Type (Volume)
        • 5.3.2.1. Ramucirumab
        • 5.3.2.2. Docetaxel
        • 5.3.2.3. Doxorubicin Hydrochloride
        • 5.3.2.4. Fluorouracil
        • 5.3.2.5. Others
      • 5.3.3. Global Gastrointestinal Cancer Drugs by: Therapy (Volume)
        • 5.3.3.1. Immunotherapy
        • 5.3.3.2. Chemotherapy
        • 5.3.3.3. Targeted Therapy
        • 5.3.3.4. Sunitinib
        • 5.3.3.5. Trastuzumab
        • 5.3.3.6. Imatinib
        • 5.3.3.7. Hormone Therapy
        • 5.3.3.8. Adjuvant Chemotherapy
        • 5.3.3.9. Radiation Therapy
        • 5.3.3.10. Others
      • 5.3.4. Global Gastrointestinal Cancer Drugs by: Distribution Channel (Volume)
        • 5.3.4.1. Hospital Pharmacies
        • 5.3.4.2. Retail Pharmacies
        • 5.3.4.3. Online
        • 5.3.4.4. Others
      • 5.3.5. Global Gastrointestinal Cancer Drugs Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Gastrointestinal Cancer Drugs (Price)
  • 6. Gastrointestinal Cancer Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bristol-Myers Squibb Company (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Roche Holding AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Eli Lilly and Company (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Johnson & Johnson (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline plc. (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Celgene Corporation (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sanofi S.A. (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novartis AG (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AstraZeneca (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Gastrointestinal Cancer Drugs Sale, by Application, Drug Type, Therapy, Distribution Channel and Region (value, volume and price ) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Gastrointestinal Cancer Drugs (Value)
      • 7.2.1. Global Gastrointestinal Cancer Drugs by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Specialized Cancer Treatment Centers
        • 7.2.1.3. Clinics
        • 7.2.1.4. Ambulatory Surgical Centers
      • 7.2.2. Global Gastrointestinal Cancer Drugs by: Drug Type (Value)
        • 7.2.2.1. Ramucirumab
        • 7.2.2.2. Docetaxel
        • 7.2.2.3. Doxorubicin Hydrochloride
        • 7.2.2.4. Fluorouracil
        • 7.2.2.5. Others
      • 7.2.3. Global Gastrointestinal Cancer Drugs by: Therapy (Value)
        • 7.2.3.1. Immunotherapy
        • 7.2.3.2. Chemotherapy
        • 7.2.3.3. Targeted Therapy
        • 7.2.3.4. Sunitinib
        • 7.2.3.5. Trastuzumab
        • 7.2.3.6. Imatinib
        • 7.2.3.7. Hormone Therapy
        • 7.2.3.8. Adjuvant Chemotherapy
        • 7.2.3.9. Radiation Therapy
        • 7.2.3.10. Others
      • 7.2.4. Global Gastrointestinal Cancer Drugs by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharmacies
        • 7.2.4.2. Retail Pharmacies
        • 7.2.4.3. Online
        • 7.2.4.4. Others
      • 7.2.5. Global Gastrointestinal Cancer Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Gastrointestinal Cancer Drugs (Volume)
      • 7.3.1. Global Gastrointestinal Cancer Drugs by: Application (Volume)
        • 7.3.1.1. Hospitals
        • 7.3.1.2. Specialized Cancer Treatment Centers
        • 7.3.1.3. Clinics
        • 7.3.1.4. Ambulatory Surgical Centers
      • 7.3.2. Global Gastrointestinal Cancer Drugs by: Drug Type (Volume)
        • 7.3.2.1. Ramucirumab
        • 7.3.2.2. Docetaxel
        • 7.3.2.3. Doxorubicin Hydrochloride
        • 7.3.2.4. Fluorouracil
        • 7.3.2.5. Others
      • 7.3.3. Global Gastrointestinal Cancer Drugs by: Therapy (Volume)
        • 7.3.3.1. Immunotherapy
        • 7.3.3.2. Chemotherapy
        • 7.3.3.3. Targeted Therapy
        • 7.3.3.4. Sunitinib
        • 7.3.3.5. Trastuzumab
        • 7.3.3.6. Imatinib
        • 7.3.3.7. Hormone Therapy
        • 7.3.3.8. Adjuvant Chemotherapy
        • 7.3.3.9. Radiation Therapy
        • 7.3.3.10. Others
      • 7.3.4. Global Gastrointestinal Cancer Drugs by: Distribution Channel (Volume)
        • 7.3.4.1. Hospital Pharmacies
        • 7.3.4.2. Retail Pharmacies
        • 7.3.4.3. Online
        • 7.3.4.4. Others
      • 7.3.5. Global Gastrointestinal Cancer Drugs Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Gastrointestinal Cancer Drugs (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Gastrointestinal Cancer Drugs: by Application(USD Million)
  • Table 2. Gastrointestinal Cancer Drugs Hospitals , by Region USD Million (2014-2019)
  • Table 3. Gastrointestinal Cancer Drugs Specialized Cancer Treatment Centers , by Region USD Million (2014-2019)
  • Table 4. Gastrointestinal Cancer Drugs Clinics , by Region USD Million (2014-2019)
  • Table 5. Gastrointestinal Cancer Drugs Ambulatory Surgical Centers , by Region USD Million (2014-2019)
  • Table 6. Gastrointestinal Cancer Drugs: by Drug Type(USD Million)
  • Table 7. Gastrointestinal Cancer Drugs Ramucirumab , by Region USD Million (2014-2019)
  • Table 8. Gastrointestinal Cancer Drugs Docetaxel , by Region USD Million (2014-2019)
  • Table 9. Gastrointestinal Cancer Drugs Doxorubicin Hydrochloride , by Region USD Million (2014-2019)
  • Table 10. Gastrointestinal Cancer Drugs Fluorouracil , by Region USD Million (2014-2019)
  • Table 11. Gastrointestinal Cancer Drugs Others , by Region USD Million (2014-2019)
  • Table 12. Gastrointestinal Cancer Drugs: by Therapy(USD Million)
  • Table 13. Gastrointestinal Cancer Drugs Immunotherapy , by Region USD Million (2014-2019)
  • Table 14. Gastrointestinal Cancer Drugs Chemotherapy , by Region USD Million (2014-2019)
  • Table 15. Gastrointestinal Cancer Drugs Targeted Therapy , by Region USD Million (2014-2019)
  • Table 16. Gastrointestinal Cancer Drugs Sunitinib , by Region USD Million (2014-2019)
  • Table 17. Gastrointestinal Cancer Drugs Trastuzumab , by Region USD Million (2014-2019)
  • Table 18. Gastrointestinal Cancer Drugs Imatinib , by Region USD Million (2014-2019)
  • Table 19. Gastrointestinal Cancer Drugs Hormone Therapy , by Region USD Million (2014-2019)
  • Table 20. Gastrointestinal Cancer Drugs Adjuvant Chemotherapy , by Region USD Million (2014-2019)
  • Table 21. Gastrointestinal Cancer Drugs Radiation Therapy , by Region USD Million (2014-2019)
  • Table 22. Gastrointestinal Cancer Drugs Others , by Region USD Million (2014-2019)
  • Table 23. Gastrointestinal Cancer Drugs: by Distribution Channel(USD Million)
  • Table 24. Gastrointestinal Cancer Drugs Hospital Pharmacies , by Region USD Million (2014-2019)
  • Table 25. Gastrointestinal Cancer Drugs Retail Pharmacies , by Region USD Million (2014-2019)
  • Table 26. Gastrointestinal Cancer Drugs Online , by Region USD Million (2014-2019)
  • Table 27. Gastrointestinal Cancer Drugs Others , by Region USD Million (2014-2019)
  • Table 28. South America Gastrointestinal Cancer Drugs, by Country USD Million (2014-2019)
  • Table 29. South America Gastrointestinal Cancer Drugs, by Application USD Million (2014-2019)
  • Table 30. South America Gastrointestinal Cancer Drugs, by Drug Type USD Million (2014-2019)
  • Table 31. South America Gastrointestinal Cancer Drugs, by Therapy USD Million (2014-2019)
  • Table 32. South America Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 33. Brazil Gastrointestinal Cancer Drugs, by Application USD Million (2014-2019)
  • Table 34. Brazil Gastrointestinal Cancer Drugs, by Drug Type USD Million (2014-2019)
  • Table 35. Brazil Gastrointestinal Cancer Drugs, by Therapy USD Million (2014-2019)
  • Table 36. Brazil Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 37. Argentina Gastrointestinal Cancer Drugs, by Application USD Million (2014-2019)
  • Table 38. Argentina Gastrointestinal Cancer Drugs, by Drug Type USD Million (2014-2019)
  • Table 39. Argentina Gastrointestinal Cancer Drugs, by Therapy USD Million (2014-2019)
  • Table 40. Argentina Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 41. Rest of South America Gastrointestinal Cancer Drugs, by Application USD Million (2014-2019)
  • Table 42. Rest of South America Gastrointestinal Cancer Drugs, by Drug Type USD Million (2014-2019)
  • Table 43. Rest of South America Gastrointestinal Cancer Drugs, by Therapy USD Million (2014-2019)
  • Table 44. Rest of South America Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 45. Asia Pacific Gastrointestinal Cancer Drugs, by Country USD Million (2014-2019)
  • Table 46. Asia Pacific Gastrointestinal Cancer Drugs, by Application USD Million (2014-2019)
  • Table 47. Asia Pacific Gastrointestinal Cancer Drugs, by Drug Type USD Million (2014-2019)
  • Table 48. Asia Pacific Gastrointestinal Cancer Drugs, by Therapy USD Million (2014-2019)
  • Table 49. Asia Pacific Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 50. China Gastrointestinal Cancer Drugs, by Application USD Million (2014-2019)
  • Table 51. China Gastrointestinal Cancer Drugs, by Drug Type USD Million (2014-2019)
  • Table 52. China Gastrointestinal Cancer Drugs, by Therapy USD Million (2014-2019)
  • Table 53. China Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 54. Japan Gastrointestinal Cancer Drugs, by Application USD Million (2014-2019)
  • Table 55. Japan Gastrointestinal Cancer Drugs, by Drug Type USD Million (2014-2019)
  • Table 56. Japan Gastrointestinal Cancer Drugs, by Therapy USD Million (2014-2019)
  • Table 57. Japan Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 58. India Gastrointestinal Cancer Drugs, by Application USD Million (2014-2019)
  • Table 59. India Gastrointestinal Cancer Drugs, by Drug Type USD Million (2014-2019)
  • Table 60. India Gastrointestinal Cancer Drugs, by Therapy USD Million (2014-2019)
  • Table 61. India Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 62. South Korea Gastrointestinal Cancer Drugs, by Application USD Million (2014-2019)
  • Table 63. South Korea Gastrointestinal Cancer Drugs, by Drug Type USD Million (2014-2019)
  • Table 64. South Korea Gastrointestinal Cancer Drugs, by Therapy USD Million (2014-2019)
  • Table 65. South Korea Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 66. Taiwan Gastrointestinal Cancer Drugs, by Application USD Million (2014-2019)
  • Table 67. Taiwan Gastrointestinal Cancer Drugs, by Drug Type USD Million (2014-2019)
  • Table 68. Taiwan Gastrointestinal Cancer Drugs, by Therapy USD Million (2014-2019)
  • Table 69. Taiwan Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 70. Australia Gastrointestinal Cancer Drugs, by Application USD Million (2014-2019)
  • Table 71. Australia Gastrointestinal Cancer Drugs, by Drug Type USD Million (2014-2019)
  • Table 72. Australia Gastrointestinal Cancer Drugs, by Therapy USD Million (2014-2019)
  • Table 73. Australia Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 74. Rest of Asia-Pacific Gastrointestinal Cancer Drugs, by Application USD Million (2014-2019)
  • Table 75. Rest of Asia-Pacific Gastrointestinal Cancer Drugs, by Drug Type USD Million (2014-2019)
  • Table 76. Rest of Asia-Pacific Gastrointestinal Cancer Drugs, by Therapy USD Million (2014-2019)
  • Table 77. Rest of Asia-Pacific Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 78. Europe Gastrointestinal Cancer Drugs, by Country USD Million (2014-2019)
  • Table 79. Europe Gastrointestinal Cancer Drugs, by Application USD Million (2014-2019)
  • Table 80. Europe Gastrointestinal Cancer Drugs, by Drug Type USD Million (2014-2019)
  • Table 81. Europe Gastrointestinal Cancer Drugs, by Therapy USD Million (2014-2019)
  • Table 82. Europe Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 83. Germany Gastrointestinal Cancer Drugs, by Application USD Million (2014-2019)
  • Table 84. Germany Gastrointestinal Cancer Drugs, by Drug Type USD Million (2014-2019)
  • Table 85. Germany Gastrointestinal Cancer Drugs, by Therapy USD Million (2014-2019)
  • Table 86. Germany Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 87. France Gastrointestinal Cancer Drugs, by Application USD Million (2014-2019)
  • Table 88. France Gastrointestinal Cancer Drugs, by Drug Type USD Million (2014-2019)
  • Table 89. France Gastrointestinal Cancer Drugs, by Therapy USD Million (2014-2019)
  • Table 90. France Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 91. Italy Gastrointestinal Cancer Drugs, by Application USD Million (2014-2019)
  • Table 92. Italy Gastrointestinal Cancer Drugs, by Drug Type USD Million (2014-2019)
  • Table 93. Italy Gastrointestinal Cancer Drugs, by Therapy USD Million (2014-2019)
  • Table 94. Italy Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 95. United Kingdom Gastrointestinal Cancer Drugs, by Application USD Million (2014-2019)
  • Table 96. United Kingdom Gastrointestinal Cancer Drugs, by Drug Type USD Million (2014-2019)
  • Table 97. United Kingdom Gastrointestinal Cancer Drugs, by Therapy USD Million (2014-2019)
  • Table 98. United Kingdom Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 99. Netherlands Gastrointestinal Cancer Drugs, by Application USD Million (2014-2019)
  • Table 100. Netherlands Gastrointestinal Cancer Drugs, by Drug Type USD Million (2014-2019)
  • Table 101. Netherlands Gastrointestinal Cancer Drugs, by Therapy USD Million (2014-2019)
  • Table 102. Netherlands Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 103. Rest of Europe Gastrointestinal Cancer Drugs, by Application USD Million (2014-2019)
  • Table 104. Rest of Europe Gastrointestinal Cancer Drugs, by Drug Type USD Million (2014-2019)
  • Table 105. Rest of Europe Gastrointestinal Cancer Drugs, by Therapy USD Million (2014-2019)
  • Table 106. Rest of Europe Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 107. MEA Gastrointestinal Cancer Drugs, by Country USD Million (2014-2019)
  • Table 108. MEA Gastrointestinal Cancer Drugs, by Application USD Million (2014-2019)
  • Table 109. MEA Gastrointestinal Cancer Drugs, by Drug Type USD Million (2014-2019)
  • Table 110. MEA Gastrointestinal Cancer Drugs, by Therapy USD Million (2014-2019)
  • Table 111. MEA Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 112. Middle East Gastrointestinal Cancer Drugs, by Application USD Million (2014-2019)
  • Table 113. Middle East Gastrointestinal Cancer Drugs, by Drug Type USD Million (2014-2019)
  • Table 114. Middle East Gastrointestinal Cancer Drugs, by Therapy USD Million (2014-2019)
  • Table 115. Middle East Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 116. Africa Gastrointestinal Cancer Drugs, by Application USD Million (2014-2019)
  • Table 117. Africa Gastrointestinal Cancer Drugs, by Drug Type USD Million (2014-2019)
  • Table 118. Africa Gastrointestinal Cancer Drugs, by Therapy USD Million (2014-2019)
  • Table 119. Africa Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 120. North America Gastrointestinal Cancer Drugs, by Country USD Million (2014-2019)
  • Table 121. North America Gastrointestinal Cancer Drugs, by Application USD Million (2014-2019)
  • Table 122. North America Gastrointestinal Cancer Drugs, by Drug Type USD Million (2014-2019)
  • Table 123. North America Gastrointestinal Cancer Drugs, by Therapy USD Million (2014-2019)
  • Table 124. North America Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 125. United States Gastrointestinal Cancer Drugs, by Application USD Million (2014-2019)
  • Table 126. United States Gastrointestinal Cancer Drugs, by Drug Type USD Million (2014-2019)
  • Table 127. United States Gastrointestinal Cancer Drugs, by Therapy USD Million (2014-2019)
  • Table 128. United States Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 129. Canada Gastrointestinal Cancer Drugs, by Application USD Million (2014-2019)
  • Table 130. Canada Gastrointestinal Cancer Drugs, by Drug Type USD Million (2014-2019)
  • Table 131. Canada Gastrointestinal Cancer Drugs, by Therapy USD Million (2014-2019)
  • Table 132. Canada Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 133. Mexico Gastrointestinal Cancer Drugs, by Application USD Million (2014-2019)
  • Table 134. Mexico Gastrointestinal Cancer Drugs, by Drug Type USD Million (2014-2019)
  • Table 135. Mexico Gastrointestinal Cancer Drugs, by Therapy USD Million (2014-2019)
  • Table 136. Mexico Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 137. Gastrointestinal Cancer Drugs Sales: by Application(K Units)
  • Table 138. Gastrointestinal Cancer Drugs Sales Hospitals , by Region K Units (2014-2019)
  • Table 139. Gastrointestinal Cancer Drugs Sales Specialized Cancer Treatment Centers , by Region K Units (2014-2019)
  • Table 140. Gastrointestinal Cancer Drugs Sales Clinics , by Region K Units (2014-2019)
  • Table 141. Gastrointestinal Cancer Drugs Sales Ambulatory Surgical Centers , by Region K Units (2014-2019)
  • Table 142. Gastrointestinal Cancer Drugs Sales: by Drug Type(K Units)
  • Table 143. Gastrointestinal Cancer Drugs Sales Ramucirumab , by Region K Units (2014-2019)
  • Table 144. Gastrointestinal Cancer Drugs Sales Docetaxel , by Region K Units (2014-2019)
  • Table 145. Gastrointestinal Cancer Drugs Sales Doxorubicin Hydrochloride , by Region K Units (2014-2019)
  • Table 146. Gastrointestinal Cancer Drugs Sales Fluorouracil , by Region K Units (2014-2019)
  • Table 147. Gastrointestinal Cancer Drugs Sales Others , by Region K Units (2014-2019)
  • Table 148. Gastrointestinal Cancer Drugs Sales: by Therapy(K Units)
  • Table 149. Gastrointestinal Cancer Drugs Sales Immunotherapy , by Region K Units (2014-2019)
  • Table 150. Gastrointestinal Cancer Drugs Sales Chemotherapy , by Region K Units (2014-2019)
  • Table 151. Gastrointestinal Cancer Drugs Sales Targeted Therapy , by Region K Units (2014-2019)
  • Table 152. Gastrointestinal Cancer Drugs Sales Sunitinib , by Region K Units (2014-2019)
  • Table 153. Gastrointestinal Cancer Drugs Sales Trastuzumab , by Region K Units (2014-2019)
  • Table 154. Gastrointestinal Cancer Drugs Sales Imatinib , by Region K Units (2014-2019)
  • Table 155. Gastrointestinal Cancer Drugs Sales Hormone Therapy , by Region K Units (2014-2019)
  • Table 156. Gastrointestinal Cancer Drugs Sales Adjuvant Chemotherapy , by Region K Units (2014-2019)
  • Table 157. Gastrointestinal Cancer Drugs Sales Radiation Therapy , by Region K Units (2014-2019)
  • Table 158. Gastrointestinal Cancer Drugs Sales Others , by Region K Units (2014-2019)
  • Table 159. Gastrointestinal Cancer Drugs Sales: by Distribution Channel(K Units)
  • Table 160. Gastrointestinal Cancer Drugs Sales Hospital Pharmacies , by Region K Units (2014-2019)
  • Table 161. Gastrointestinal Cancer Drugs Sales Retail Pharmacies , by Region K Units (2014-2019)
  • Table 162. Gastrointestinal Cancer Drugs Sales Online , by Region K Units (2014-2019)
  • Table 163. Gastrointestinal Cancer Drugs Sales Others , by Region K Units (2014-2019)
  • Table 164. South America Gastrointestinal Cancer Drugs Sales, by Country K Units (2014-2019)
  • Table 165. South America Gastrointestinal Cancer Drugs Sales, by Application K Units (2014-2019)
  • Table 166. South America Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2014-2019)
  • Table 167. South America Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2014-2019)
  • Table 168. South America Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 169. Brazil Gastrointestinal Cancer Drugs Sales, by Application K Units (2014-2019)
  • Table 170. Brazil Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2014-2019)
  • Table 171. Brazil Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2014-2019)
  • Table 172. Brazil Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 173. Argentina Gastrointestinal Cancer Drugs Sales, by Application K Units (2014-2019)
  • Table 174. Argentina Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2014-2019)
  • Table 175. Argentina Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2014-2019)
  • Table 176. Argentina Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 177. Rest of South America Gastrointestinal Cancer Drugs Sales, by Application K Units (2014-2019)
  • Table 178. Rest of South America Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2014-2019)
  • Table 179. Rest of South America Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2014-2019)
  • Table 180. Rest of South America Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 181. Asia Pacific Gastrointestinal Cancer Drugs Sales, by Country K Units (2014-2019)
  • Table 182. Asia Pacific Gastrointestinal Cancer Drugs Sales, by Application K Units (2014-2019)
  • Table 183. Asia Pacific Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2014-2019)
  • Table 184. Asia Pacific Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2014-2019)
  • Table 185. Asia Pacific Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 186. China Gastrointestinal Cancer Drugs Sales, by Application K Units (2014-2019)
  • Table 187. China Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2014-2019)
  • Table 188. China Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2014-2019)
  • Table 189. China Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 190. Japan Gastrointestinal Cancer Drugs Sales, by Application K Units (2014-2019)
  • Table 191. Japan Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2014-2019)
  • Table 192. Japan Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2014-2019)
  • Table 193. Japan Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 194. India Gastrointestinal Cancer Drugs Sales, by Application K Units (2014-2019)
  • Table 195. India Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2014-2019)
  • Table 196. India Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2014-2019)
  • Table 197. India Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 198. South Korea Gastrointestinal Cancer Drugs Sales, by Application K Units (2014-2019)
  • Table 199. South Korea Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2014-2019)
  • Table 200. South Korea Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2014-2019)
  • Table 201. South Korea Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 202. Taiwan Gastrointestinal Cancer Drugs Sales, by Application K Units (2014-2019)
  • Table 203. Taiwan Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2014-2019)
  • Table 204. Taiwan Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2014-2019)
  • Table 205. Taiwan Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 206. Australia Gastrointestinal Cancer Drugs Sales, by Application K Units (2014-2019)
  • Table 207. Australia Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2014-2019)
  • Table 208. Australia Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2014-2019)
  • Table 209. Australia Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 210. Rest of Asia-Pacific Gastrointestinal Cancer Drugs Sales, by Application K Units (2014-2019)
  • Table 211. Rest of Asia-Pacific Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2014-2019)
  • Table 212. Rest of Asia-Pacific Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2014-2019)
  • Table 213. Rest of Asia-Pacific Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 214. Europe Gastrointestinal Cancer Drugs Sales, by Country K Units (2014-2019)
  • Table 215. Europe Gastrointestinal Cancer Drugs Sales, by Application K Units (2014-2019)
  • Table 216. Europe Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2014-2019)
  • Table 217. Europe Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2014-2019)
  • Table 218. Europe Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 219. Germany Gastrointestinal Cancer Drugs Sales, by Application K Units (2014-2019)
  • Table 220. Germany Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2014-2019)
  • Table 221. Germany Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2014-2019)
  • Table 222. Germany Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 223. France Gastrointestinal Cancer Drugs Sales, by Application K Units (2014-2019)
  • Table 224. France Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2014-2019)
  • Table 225. France Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2014-2019)
  • Table 226. France Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 227. Italy Gastrointestinal Cancer Drugs Sales, by Application K Units (2014-2019)
  • Table 228. Italy Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2014-2019)
  • Table 229. Italy Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2014-2019)
  • Table 230. Italy Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 231. United Kingdom Gastrointestinal Cancer Drugs Sales, by Application K Units (2014-2019)
  • Table 232. United Kingdom Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2014-2019)
  • Table 233. United Kingdom Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2014-2019)
  • Table 234. United Kingdom Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 235. Netherlands Gastrointestinal Cancer Drugs Sales, by Application K Units (2014-2019)
  • Table 236. Netherlands Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2014-2019)
  • Table 237. Netherlands Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2014-2019)
  • Table 238. Netherlands Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 239. Rest of Europe Gastrointestinal Cancer Drugs Sales, by Application K Units (2014-2019)
  • Table 240. Rest of Europe Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2014-2019)
  • Table 241. Rest of Europe Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2014-2019)
  • Table 242. Rest of Europe Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 243. MEA Gastrointestinal Cancer Drugs Sales, by Country K Units (2014-2019)
  • Table 244. MEA Gastrointestinal Cancer Drugs Sales, by Application K Units (2014-2019)
  • Table 245. MEA Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2014-2019)
  • Table 246. MEA Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2014-2019)
  • Table 247. MEA Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 248. Middle East Gastrointestinal Cancer Drugs Sales, by Application K Units (2014-2019)
  • Table 249. Middle East Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2014-2019)
  • Table 250. Middle East Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2014-2019)
  • Table 251. Middle East Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 252. Africa Gastrointestinal Cancer Drugs Sales, by Application K Units (2014-2019)
  • Table 253. Africa Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2014-2019)
  • Table 254. Africa Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2014-2019)
  • Table 255. Africa Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 256. North America Gastrointestinal Cancer Drugs Sales, by Country K Units (2014-2019)
  • Table 257. North America Gastrointestinal Cancer Drugs Sales, by Application K Units (2014-2019)
  • Table 258. North America Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2014-2019)
  • Table 259. North America Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2014-2019)
  • Table 260. North America Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 261. United States Gastrointestinal Cancer Drugs Sales, by Application K Units (2014-2019)
  • Table 262. United States Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2014-2019)
  • Table 263. United States Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2014-2019)
  • Table 264. United States Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 265. Canada Gastrointestinal Cancer Drugs Sales, by Application K Units (2014-2019)
  • Table 266. Canada Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2014-2019)
  • Table 267. Canada Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2014-2019)
  • Table 268. Canada Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 269. Mexico Gastrointestinal Cancer Drugs Sales, by Application K Units (2014-2019)
  • Table 270. Mexico Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2014-2019)
  • Table 271. Mexico Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2014-2019)
  • Table 272. Mexico Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 273. Company Basic Information, Sales Area and Its Competitors
  • Table 274. Company Basic Information, Sales Area and Its Competitors
  • Table 275. Company Basic Information, Sales Area and Its Competitors
  • Table 276. Company Basic Information, Sales Area and Its Competitors
  • Table 277. Company Basic Information, Sales Area and Its Competitors
  • Table 278. Company Basic Information, Sales Area and Its Competitors
  • Table 279. Company Basic Information, Sales Area and Its Competitors
  • Table 280. Company Basic Information, Sales Area and Its Competitors
  • Table 281. Company Basic Information, Sales Area and Its Competitors
  • Table 282. Company Basic Information, Sales Area and Its Competitors
  • Table 283. Gastrointestinal Cancer Drugs: by Application(USD Million)
  • Table 284. Gastrointestinal Cancer Drugs Hospitals , by Region USD Million (2020-2025)
  • Table 285. Gastrointestinal Cancer Drugs Specialized Cancer Treatment Centers , by Region USD Million (2020-2025)
  • Table 286. Gastrointestinal Cancer Drugs Clinics , by Region USD Million (2020-2025)
  • Table 287. Gastrointestinal Cancer Drugs Ambulatory Surgical Centers , by Region USD Million (2020-2025)
  • Table 288. Gastrointestinal Cancer Drugs: by Drug Type(USD Million)
  • Table 289. Gastrointestinal Cancer Drugs Ramucirumab , by Region USD Million (2020-2025)
  • Table 290. Gastrointestinal Cancer Drugs Docetaxel , by Region USD Million (2020-2025)
  • Table 291. Gastrointestinal Cancer Drugs Doxorubicin Hydrochloride , by Region USD Million (2020-2025)
  • Table 292. Gastrointestinal Cancer Drugs Fluorouracil , by Region USD Million (2020-2025)
  • Table 293. Gastrointestinal Cancer Drugs Others , by Region USD Million (2020-2025)
  • Table 294. Gastrointestinal Cancer Drugs: by Therapy(USD Million)
  • Table 295. Gastrointestinal Cancer Drugs Immunotherapy , by Region USD Million (2020-2025)
  • Table 296. Gastrointestinal Cancer Drugs Chemotherapy , by Region USD Million (2020-2025)
  • Table 297. Gastrointestinal Cancer Drugs Targeted Therapy , by Region USD Million (2020-2025)
  • Table 298. Gastrointestinal Cancer Drugs Sunitinib , by Region USD Million (2020-2025)
  • Table 299. Gastrointestinal Cancer Drugs Trastuzumab , by Region USD Million (2020-2025)
  • Table 300. Gastrointestinal Cancer Drugs Imatinib , by Region USD Million (2020-2025)
  • Table 301. Gastrointestinal Cancer Drugs Hormone Therapy , by Region USD Million (2020-2025)
  • Table 302. Gastrointestinal Cancer Drugs Adjuvant Chemotherapy , by Region USD Million (2020-2025)
  • Table 303. Gastrointestinal Cancer Drugs Radiation Therapy , by Region USD Million (2020-2025)
  • Table 304. Gastrointestinal Cancer Drugs Others , by Region USD Million (2020-2025)
  • Table 305. Gastrointestinal Cancer Drugs: by Distribution Channel(USD Million)
  • Table 306. Gastrointestinal Cancer Drugs Hospital Pharmacies , by Region USD Million (2020-2025)
  • Table 307. Gastrointestinal Cancer Drugs Retail Pharmacies , by Region USD Million (2020-2025)
  • Table 308. Gastrointestinal Cancer Drugs Online , by Region USD Million (2020-2025)
  • Table 309. Gastrointestinal Cancer Drugs Others , by Region USD Million (2020-2025)
  • Table 310. South America Gastrointestinal Cancer Drugs, by Country USD Million (2020-2025)
  • Table 311. South America Gastrointestinal Cancer Drugs, by Application USD Million (2020-2025)
  • Table 312. South America Gastrointestinal Cancer Drugs, by Drug Type USD Million (2020-2025)
  • Table 313. South America Gastrointestinal Cancer Drugs, by Therapy USD Million (2020-2025)
  • Table 314. South America Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 315. Brazil Gastrointestinal Cancer Drugs, by Application USD Million (2020-2025)
  • Table 316. Brazil Gastrointestinal Cancer Drugs, by Drug Type USD Million (2020-2025)
  • Table 317. Brazil Gastrointestinal Cancer Drugs, by Therapy USD Million (2020-2025)
  • Table 318. Brazil Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 319. Argentina Gastrointestinal Cancer Drugs, by Application USD Million (2020-2025)
  • Table 320. Argentina Gastrointestinal Cancer Drugs, by Drug Type USD Million (2020-2025)
  • Table 321. Argentina Gastrointestinal Cancer Drugs, by Therapy USD Million (2020-2025)
  • Table 322. Argentina Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 323. Rest of South America Gastrointestinal Cancer Drugs, by Application USD Million (2020-2025)
  • Table 324. Rest of South America Gastrointestinal Cancer Drugs, by Drug Type USD Million (2020-2025)
  • Table 325. Rest of South America Gastrointestinal Cancer Drugs, by Therapy USD Million (2020-2025)
  • Table 326. Rest of South America Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 327. Asia Pacific Gastrointestinal Cancer Drugs, by Country USD Million (2020-2025)
  • Table 328. Asia Pacific Gastrointestinal Cancer Drugs, by Application USD Million (2020-2025)
  • Table 329. Asia Pacific Gastrointestinal Cancer Drugs, by Drug Type USD Million (2020-2025)
  • Table 330. Asia Pacific Gastrointestinal Cancer Drugs, by Therapy USD Million (2020-2025)
  • Table 331. Asia Pacific Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 332. China Gastrointestinal Cancer Drugs, by Application USD Million (2020-2025)
  • Table 333. China Gastrointestinal Cancer Drugs, by Drug Type USD Million (2020-2025)
  • Table 334. China Gastrointestinal Cancer Drugs, by Therapy USD Million (2020-2025)
  • Table 335. China Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 336. Japan Gastrointestinal Cancer Drugs, by Application USD Million (2020-2025)
  • Table 337. Japan Gastrointestinal Cancer Drugs, by Drug Type USD Million (2020-2025)
  • Table 338. Japan Gastrointestinal Cancer Drugs, by Therapy USD Million (2020-2025)
  • Table 339. Japan Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 340. India Gastrointestinal Cancer Drugs, by Application USD Million (2020-2025)
  • Table 341. India Gastrointestinal Cancer Drugs, by Drug Type USD Million (2020-2025)
  • Table 342. India Gastrointestinal Cancer Drugs, by Therapy USD Million (2020-2025)
  • Table 343. India Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 344. South Korea Gastrointestinal Cancer Drugs, by Application USD Million (2020-2025)
  • Table 345. South Korea Gastrointestinal Cancer Drugs, by Drug Type USD Million (2020-2025)
  • Table 346. South Korea Gastrointestinal Cancer Drugs, by Therapy USD Million (2020-2025)
  • Table 347. South Korea Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 348. Taiwan Gastrointestinal Cancer Drugs, by Application USD Million (2020-2025)
  • Table 349. Taiwan Gastrointestinal Cancer Drugs, by Drug Type USD Million (2020-2025)
  • Table 350. Taiwan Gastrointestinal Cancer Drugs, by Therapy USD Million (2020-2025)
  • Table 351. Taiwan Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 352. Australia Gastrointestinal Cancer Drugs, by Application USD Million (2020-2025)
  • Table 353. Australia Gastrointestinal Cancer Drugs, by Drug Type USD Million (2020-2025)
  • Table 354. Australia Gastrointestinal Cancer Drugs, by Therapy USD Million (2020-2025)
  • Table 355. Australia Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 356. Rest of Asia-Pacific Gastrointestinal Cancer Drugs, by Application USD Million (2020-2025)
  • Table 357. Rest of Asia-Pacific Gastrointestinal Cancer Drugs, by Drug Type USD Million (2020-2025)
  • Table 358. Rest of Asia-Pacific Gastrointestinal Cancer Drugs, by Therapy USD Million (2020-2025)
  • Table 359. Rest of Asia-Pacific Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 360. Europe Gastrointestinal Cancer Drugs, by Country USD Million (2020-2025)
  • Table 361. Europe Gastrointestinal Cancer Drugs, by Application USD Million (2020-2025)
  • Table 362. Europe Gastrointestinal Cancer Drugs, by Drug Type USD Million (2020-2025)
  • Table 363. Europe Gastrointestinal Cancer Drugs, by Therapy USD Million (2020-2025)
  • Table 364. Europe Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 365. Germany Gastrointestinal Cancer Drugs, by Application USD Million (2020-2025)
  • Table 366. Germany Gastrointestinal Cancer Drugs, by Drug Type USD Million (2020-2025)
  • Table 367. Germany Gastrointestinal Cancer Drugs, by Therapy USD Million (2020-2025)
  • Table 368. Germany Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 369. France Gastrointestinal Cancer Drugs, by Application USD Million (2020-2025)
  • Table 370. France Gastrointestinal Cancer Drugs, by Drug Type USD Million (2020-2025)
  • Table 371. France Gastrointestinal Cancer Drugs, by Therapy USD Million (2020-2025)
  • Table 372. France Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 373. Italy Gastrointestinal Cancer Drugs, by Application USD Million (2020-2025)
  • Table 374. Italy Gastrointestinal Cancer Drugs, by Drug Type USD Million (2020-2025)
  • Table 375. Italy Gastrointestinal Cancer Drugs, by Therapy USD Million (2020-2025)
  • Table 376. Italy Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 377. United Kingdom Gastrointestinal Cancer Drugs, by Application USD Million (2020-2025)
  • Table 378. United Kingdom Gastrointestinal Cancer Drugs, by Drug Type USD Million (2020-2025)
  • Table 379. United Kingdom Gastrointestinal Cancer Drugs, by Therapy USD Million (2020-2025)
  • Table 380. United Kingdom Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 381. Netherlands Gastrointestinal Cancer Drugs, by Application USD Million (2020-2025)
  • Table 382. Netherlands Gastrointestinal Cancer Drugs, by Drug Type USD Million (2020-2025)
  • Table 383. Netherlands Gastrointestinal Cancer Drugs, by Therapy USD Million (2020-2025)
  • Table 384. Netherlands Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 385. Rest of Europe Gastrointestinal Cancer Drugs, by Application USD Million (2020-2025)
  • Table 386. Rest of Europe Gastrointestinal Cancer Drugs, by Drug Type USD Million (2020-2025)
  • Table 387. Rest of Europe Gastrointestinal Cancer Drugs, by Therapy USD Million (2020-2025)
  • Table 388. Rest of Europe Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 389. MEA Gastrointestinal Cancer Drugs, by Country USD Million (2020-2025)
  • Table 390. MEA Gastrointestinal Cancer Drugs, by Application USD Million (2020-2025)
  • Table 391. MEA Gastrointestinal Cancer Drugs, by Drug Type USD Million (2020-2025)
  • Table 392. MEA Gastrointestinal Cancer Drugs, by Therapy USD Million (2020-2025)
  • Table 393. MEA Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 394. Middle East Gastrointestinal Cancer Drugs, by Application USD Million (2020-2025)
  • Table 395. Middle East Gastrointestinal Cancer Drugs, by Drug Type USD Million (2020-2025)
  • Table 396. Middle East Gastrointestinal Cancer Drugs, by Therapy USD Million (2020-2025)
  • Table 397. Middle East Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 398. Africa Gastrointestinal Cancer Drugs, by Application USD Million (2020-2025)
  • Table 399. Africa Gastrointestinal Cancer Drugs, by Drug Type USD Million (2020-2025)
  • Table 400. Africa Gastrointestinal Cancer Drugs, by Therapy USD Million (2020-2025)
  • Table 401. Africa Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 402. North America Gastrointestinal Cancer Drugs, by Country USD Million (2020-2025)
  • Table 403. North America Gastrointestinal Cancer Drugs, by Application USD Million (2020-2025)
  • Table 404. North America Gastrointestinal Cancer Drugs, by Drug Type USD Million (2020-2025)
  • Table 405. North America Gastrointestinal Cancer Drugs, by Therapy USD Million (2020-2025)
  • Table 406. North America Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 407. United States Gastrointestinal Cancer Drugs, by Application USD Million (2020-2025)
  • Table 408. United States Gastrointestinal Cancer Drugs, by Drug Type USD Million (2020-2025)
  • Table 409. United States Gastrointestinal Cancer Drugs, by Therapy USD Million (2020-2025)
  • Table 410. United States Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 411. Canada Gastrointestinal Cancer Drugs, by Application USD Million (2020-2025)
  • Table 412. Canada Gastrointestinal Cancer Drugs, by Drug Type USD Million (2020-2025)
  • Table 413. Canada Gastrointestinal Cancer Drugs, by Therapy USD Million (2020-2025)
  • Table 414. Canada Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 415. Mexico Gastrointestinal Cancer Drugs, by Application USD Million (2020-2025)
  • Table 416. Mexico Gastrointestinal Cancer Drugs, by Drug Type USD Million (2020-2025)
  • Table 417. Mexico Gastrointestinal Cancer Drugs, by Therapy USD Million (2020-2025)
  • Table 418. Mexico Gastrointestinal Cancer Drugs, by Distribution Channel USD Million (2020-2025)
  • Table 419. Gastrointestinal Cancer Drugs Sales: by Application(K Units)
  • Table 420. Gastrointestinal Cancer Drugs Sales Hospitals , by Region K Units (2020-2025)
  • Table 421. Gastrointestinal Cancer Drugs Sales Specialized Cancer Treatment Centers , by Region K Units (2020-2025)
  • Table 422. Gastrointestinal Cancer Drugs Sales Clinics , by Region K Units (2020-2025)
  • Table 423. Gastrointestinal Cancer Drugs Sales Ambulatory Surgical Centers , by Region K Units (2020-2025)
  • Table 424. Gastrointestinal Cancer Drugs Sales: by Drug Type(K Units)
  • Table 425. Gastrointestinal Cancer Drugs Sales Ramucirumab , by Region K Units (2020-2025)
  • Table 426. Gastrointestinal Cancer Drugs Sales Docetaxel , by Region K Units (2020-2025)
  • Table 427. Gastrointestinal Cancer Drugs Sales Doxorubicin Hydrochloride , by Region K Units (2020-2025)
  • Table 428. Gastrointestinal Cancer Drugs Sales Fluorouracil , by Region K Units (2020-2025)
  • Table 429. Gastrointestinal Cancer Drugs Sales Others , by Region K Units (2020-2025)
  • Table 430. Gastrointestinal Cancer Drugs Sales: by Therapy(K Units)
  • Table 431. Gastrointestinal Cancer Drugs Sales Immunotherapy , by Region K Units (2020-2025)
  • Table 432. Gastrointestinal Cancer Drugs Sales Chemotherapy , by Region K Units (2020-2025)
  • Table 433. Gastrointestinal Cancer Drugs Sales Targeted Therapy , by Region K Units (2020-2025)
  • Table 434. Gastrointestinal Cancer Drugs Sales Sunitinib , by Region K Units (2020-2025)
  • Table 435. Gastrointestinal Cancer Drugs Sales Trastuzumab , by Region K Units (2020-2025)
  • Table 436. Gastrointestinal Cancer Drugs Sales Imatinib , by Region K Units (2020-2025)
  • Table 437. Gastrointestinal Cancer Drugs Sales Hormone Therapy , by Region K Units (2020-2025)
  • Table 438. Gastrointestinal Cancer Drugs Sales Adjuvant Chemotherapy , by Region K Units (2020-2025)
  • Table 439. Gastrointestinal Cancer Drugs Sales Radiation Therapy , by Region K Units (2020-2025)
  • Table 440. Gastrointestinal Cancer Drugs Sales Others , by Region K Units (2020-2025)
  • Table 441. Gastrointestinal Cancer Drugs Sales: by Distribution Channel(K Units)
  • Table 442. Gastrointestinal Cancer Drugs Sales Hospital Pharmacies , by Region K Units (2020-2025)
  • Table 443. Gastrointestinal Cancer Drugs Sales Retail Pharmacies , by Region K Units (2020-2025)
  • Table 444. Gastrointestinal Cancer Drugs Sales Online , by Region K Units (2020-2025)
  • Table 445. Gastrointestinal Cancer Drugs Sales Others , by Region K Units (2020-2025)
  • Table 446. South America Gastrointestinal Cancer Drugs Sales, by Country K Units (2020-2025)
  • Table 447. South America Gastrointestinal Cancer Drugs Sales, by Application K Units (2020-2025)
  • Table 448. South America Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2020-2025)
  • Table 449. South America Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2020-2025)
  • Table 450. South America Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2020-2025)
  • Table 451. Brazil Gastrointestinal Cancer Drugs Sales, by Application K Units (2020-2025)
  • Table 452. Brazil Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2020-2025)
  • Table 453. Brazil Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2020-2025)
  • Table 454. Brazil Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2020-2025)
  • Table 455. Argentina Gastrointestinal Cancer Drugs Sales, by Application K Units (2020-2025)
  • Table 456. Argentina Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2020-2025)
  • Table 457. Argentina Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2020-2025)
  • Table 458. Argentina Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2020-2025)
  • Table 459. Rest of South America Gastrointestinal Cancer Drugs Sales, by Application K Units (2020-2025)
  • Table 460. Rest of South America Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2020-2025)
  • Table 461. Rest of South America Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2020-2025)
  • Table 462. Rest of South America Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2020-2025)
  • Table 463. Asia Pacific Gastrointestinal Cancer Drugs Sales, by Country K Units (2020-2025)
  • Table 464. Asia Pacific Gastrointestinal Cancer Drugs Sales, by Application K Units (2020-2025)
  • Table 465. Asia Pacific Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2020-2025)
  • Table 466. Asia Pacific Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2020-2025)
  • Table 467. Asia Pacific Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2020-2025)
  • Table 468. China Gastrointestinal Cancer Drugs Sales, by Application K Units (2020-2025)
  • Table 469. China Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2020-2025)
  • Table 470. China Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2020-2025)
  • Table 471. China Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2020-2025)
  • Table 472. Japan Gastrointestinal Cancer Drugs Sales, by Application K Units (2020-2025)
  • Table 473. Japan Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2020-2025)
  • Table 474. Japan Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2020-2025)
  • Table 475. Japan Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2020-2025)
  • Table 476. India Gastrointestinal Cancer Drugs Sales, by Application K Units (2020-2025)
  • Table 477. India Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2020-2025)
  • Table 478. India Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2020-2025)
  • Table 479. India Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2020-2025)
  • Table 480. South Korea Gastrointestinal Cancer Drugs Sales, by Application K Units (2020-2025)
  • Table 481. South Korea Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2020-2025)
  • Table 482. South Korea Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2020-2025)
  • Table 483. South Korea Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2020-2025)
  • Table 484. Taiwan Gastrointestinal Cancer Drugs Sales, by Application K Units (2020-2025)
  • Table 485. Taiwan Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2020-2025)
  • Table 486. Taiwan Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2020-2025)
  • Table 487. Taiwan Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2020-2025)
  • Table 488. Australia Gastrointestinal Cancer Drugs Sales, by Application K Units (2020-2025)
  • Table 489. Australia Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2020-2025)
  • Table 490. Australia Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2020-2025)
  • Table 491. Australia Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2020-2025)
  • Table 492. Rest of Asia-Pacific Gastrointestinal Cancer Drugs Sales, by Application K Units (2020-2025)
  • Table 493. Rest of Asia-Pacific Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2020-2025)
  • Table 494. Rest of Asia-Pacific Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2020-2025)
  • Table 495. Rest of Asia-Pacific Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2020-2025)
  • Table 496. Europe Gastrointestinal Cancer Drugs Sales, by Country K Units (2020-2025)
  • Table 497. Europe Gastrointestinal Cancer Drugs Sales, by Application K Units (2020-2025)
  • Table 498. Europe Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2020-2025)
  • Table 499. Europe Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2020-2025)
  • Table 500. Europe Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2020-2025)
  • Table 501. Germany Gastrointestinal Cancer Drugs Sales, by Application K Units (2020-2025)
  • Table 502. Germany Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2020-2025)
  • Table 503. Germany Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2020-2025)
  • Table 504. Germany Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2020-2025)
  • Table 505. France Gastrointestinal Cancer Drugs Sales, by Application K Units (2020-2025)
  • Table 506. France Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2020-2025)
  • Table 507. France Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2020-2025)
  • Table 508. France Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2020-2025)
  • Table 509. Italy Gastrointestinal Cancer Drugs Sales, by Application K Units (2020-2025)
  • Table 510. Italy Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2020-2025)
  • Table 511. Italy Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2020-2025)
  • Table 512. Italy Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2020-2025)
  • Table 513. United Kingdom Gastrointestinal Cancer Drugs Sales, by Application K Units (2020-2025)
  • Table 514. United Kingdom Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2020-2025)
  • Table 515. United Kingdom Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2020-2025)
  • Table 516. United Kingdom Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2020-2025)
  • Table 517. Netherlands Gastrointestinal Cancer Drugs Sales, by Application K Units (2020-2025)
  • Table 518. Netherlands Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2020-2025)
  • Table 519. Netherlands Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2020-2025)
  • Table 520. Netherlands Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2020-2025)
  • Table 521. Rest of Europe Gastrointestinal Cancer Drugs Sales, by Application K Units (2020-2025)
  • Table 522. Rest of Europe Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2020-2025)
  • Table 523. Rest of Europe Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2020-2025)
  • Table 524. Rest of Europe Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2020-2025)
  • Table 525. MEA Gastrointestinal Cancer Drugs Sales, by Country K Units (2020-2025)
  • Table 526. MEA Gastrointestinal Cancer Drugs Sales, by Application K Units (2020-2025)
  • Table 527. MEA Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2020-2025)
  • Table 528. MEA Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2020-2025)
  • Table 529. MEA Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2020-2025)
  • Table 530. Middle East Gastrointestinal Cancer Drugs Sales, by Application K Units (2020-2025)
  • Table 531. Middle East Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2020-2025)
  • Table 532. Middle East Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2020-2025)
  • Table 533. Middle East Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2020-2025)
  • Table 534. Africa Gastrointestinal Cancer Drugs Sales, by Application K Units (2020-2025)
  • Table 535. Africa Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2020-2025)
  • Table 536. Africa Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2020-2025)
  • Table 537. Africa Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2020-2025)
  • Table 538. North America Gastrointestinal Cancer Drugs Sales, by Country K Units (2020-2025)
  • Table 539. North America Gastrointestinal Cancer Drugs Sales, by Application K Units (2020-2025)
  • Table 540. North America Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2020-2025)
  • Table 541. North America Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2020-2025)
  • Table 542. North America Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2020-2025)
  • Table 543. United States Gastrointestinal Cancer Drugs Sales, by Application K Units (2020-2025)
  • Table 544. United States Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2020-2025)
  • Table 545. United States Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2020-2025)
  • Table 546. United States Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2020-2025)
  • Table 547. Canada Gastrointestinal Cancer Drugs Sales, by Application K Units (2020-2025)
  • Table 548. Canada Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2020-2025)
  • Table 549. Canada Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2020-2025)
  • Table 550. Canada Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2020-2025)
  • Table 551. Mexico Gastrointestinal Cancer Drugs Sales, by Application K Units (2020-2025)
  • Table 552. Mexico Gastrointestinal Cancer Drugs Sales, by Drug Type K Units (2020-2025)
  • Table 553. Mexico Gastrointestinal Cancer Drugs Sales, by Therapy K Units (2020-2025)
  • Table 554. Mexico Gastrointestinal Cancer Drugs Sales, by Distribution Channel K Units (2020-2025)
  • Table 555. Research Programs/Design for This Report
  • Table 556. Key Data Information from Secondary Sources
  • Table 557. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Gastrointestinal Cancer Drugs: by Application USD Million (2014-2019)
  • Figure 5. Global Gastrointestinal Cancer Drugs: by Drug Type USD Million (2014-2019)
  • Figure 6. Global Gastrointestinal Cancer Drugs: by Therapy USD Million (2014-2019)
  • Figure 7. Global Gastrointestinal Cancer Drugs: by Distribution Channel USD Million (2014-2019)
  • Figure 8. South America Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 9. Asia Pacific Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 10. Europe Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 11. MEA Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 12. North America Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 13. Global Gastrointestinal Cancer Drugs: by Application K Units (2014-2019)
  • Figure 14. Global Gastrointestinal Cancer Drugs: by Drug Type K Units (2014-2019)
  • Figure 15. Global Gastrointestinal Cancer Drugs: by Therapy K Units (2014-2019)
  • Figure 16. Global Gastrointestinal Cancer Drugs: by Distribution Channel K Units (2014-2019)
  • Figure 17. South America Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 18. Asia Pacific Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 19. Europe Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 20. MEA Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 21. North America Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 22. Global Gastrointestinal Cancer Drugs share by Players 2019 (%)
  • Figure 23. Global Gastrointestinal Cancer Drugs share by Players (Top 3) 2019(%)
  • Figure 24. Global Gastrointestinal Cancer Drugs share by Players (Top 5) 2019(%)
  • Figure 25. BCG Matrix for key Companies
  • Figure 26. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 27. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2019
  • Figure 28. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. Roche Holding AG (Switzerland) Revenue: by Geography 2019
  • Figure 30. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 31. Eli Lilly and Company (United States) Revenue: by Geography 2019
  • Figure 32. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 33. Johnson & Johnson (United States) Revenue: by Geography 2019
  • Figure 34. GlaxoSmithKline plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 35. GlaxoSmithKline plc. (United Kingdom) Revenue: by Geography 2019
  • Figure 36. Celgene Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 37. Celgene Corporation (United States) Revenue: by Geography 2019
  • Figure 38. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 39. Pfizer Inc. (United States) Revenue: by Geography 2019
  • Figure 40. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 41. Sanofi S.A. (France) Revenue: by Geography 2019
  • Figure 42. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 43. Novartis AG (Switzerland) Revenue: by Geography 2019
  • Figure 44. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 45. AstraZeneca (United Kingdom) Revenue: by Geography 2019
  • Figure 46. Global Gastrointestinal Cancer Drugs: by Application USD Million (2020-2025)
  • Figure 47. Global Gastrointestinal Cancer Drugs: by Drug Type USD Million (2020-2025)
  • Figure 48. Global Gastrointestinal Cancer Drugs: by Therapy USD Million (2020-2025)
  • Figure 49. Global Gastrointestinal Cancer Drugs: by Distribution Channel USD Million (2020-2025)
  • Figure 50. South America Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 51. Asia Pacific Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 52. Europe Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 53. MEA Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 54. North America Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 55. Global Gastrointestinal Cancer Drugs: by Application K Units (2020-2025)
  • Figure 56. Global Gastrointestinal Cancer Drugs: by Drug Type K Units (2020-2025)
  • Figure 57. Global Gastrointestinal Cancer Drugs: by Therapy K Units (2020-2025)
  • Figure 58. Global Gastrointestinal Cancer Drugs: by Distribution Channel K Units (2020-2025)
  • Figure 59. South America Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 60. Asia Pacific Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 61. Europe Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 62. MEA Gastrointestinal Cancer Drugs Share (%), by Country
  • Figure 63. North America Gastrointestinal Cancer Drugs Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Bristol-Myers Squibb Company (United States)
  • Roche Holding AG (Switzerland)
  • Eli Lilly and Company (United States)
  • Johnson & Johnson (United States)
  • GlaxoSmithKline plc. (United Kingdom)
  • Celgene Corporation (United States)
  • Pfizer Inc. (United States)
  • Sanofi S.A. (France)
  • Novartis AG (Switzerland)
  • AstraZeneca (United Kingdom)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation